Pros and Cons of Genus plc in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 2.360% | -3.704% | -2.256% | 11.111% | -11.565% | -10.653% | -56.303% |
| Ligand Pharmaceuticals | 2.970% | 1.980% | 3.518% | 126.374% | 24.096% | 209.774% | 122.270% |
| United Therapeutics | -0.420% | -1.202% | -2.594% | 70.504% | 11.608% | 133.431% | 228.897% |
| Ionis Pharmaceuticals Inc. | -0.930% | -1.464% | 0.466% | 109.737% | -4.915% | 63.761% | 127.696% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat